48 related articles for article (PubMed ID: 38530880)
1. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
[TBL] [Abstract][Full Text] [Related]
2. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
Mazzulli JR; Xu YH; Sun Y; Knight AL; McLean PJ; Caldwell GA; Sidransky E; Grabowski GA; Krainc D
Cell; 2011 Jul; 146(1):37-52. PubMed ID: 21700325
[TBL] [Abstract][Full Text] [Related]
3. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
4. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.
Xu YH; Sun Y; Ran H; Quinn B; Witte D; Grabowski GA
Mol Genet Metab; 2011 Apr; 102(4):436-47. PubMed ID: 21257328
[TBL] [Abstract][Full Text] [Related]
5. Glucosylceramide accumulation in microglia triggers STING-dependent neuroinflammation and neurodegeneration in mice.
Wang R; Sun H; Cao Y; Zhang Z; Chen Y; Wang X; Liu L; Wu J; Xu H; Wu D; Mu C; Hao Z; Qin S; Ren H; Han J; Fang M; Wang G
Sci Signal; 2024 Mar; 17(829):eadk8249. PubMed ID: 38530880
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
7. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
8. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
9. The neuroinflammatory role of glucocerebrosidase in Parkinson's disease.
Bo RX; Li YY; Zhou TT; Chen NH; Yuan YH
Neuropharmacology; 2022 Apr; 207():108964. PubMed ID: 35065083
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
11. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]